Yale Cancer Center Smilow Cancer Hospital
Episodes
Specialty:
All
All AI for Oncology Biosimilars Brain Cancer Breast Cancer CAR T-Cell Therapy Disparities in Cancer Care Gastrointestinal Cancer Genitourinary Cancers Global Oncology Graft-vs-Host Disease Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Pediatric Oncology Precision Medicine in Oncology® Sarcomas Supportive Care
Year:
All
All 2023 2022 2021 2015
EP. 31: Patient Scenario 2: 1L Management of ES-SCLC Positive for Synaptophysin With a Ki-67 Score of 90% By Taofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center, Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital, Jacob Sands, MD, Dana-Farber Cancer Institute, Konstantinos Leventakos, MD, PhD Mayo Clinic Expert oncologists present the case of a 45-year-old woman with synaptophysin-positive, extensive-stage small-cell lung cancer with a Ki-67 score of 90%, who is treated with carboplatin, etoposide, and atezolizumab in the first-line setting, and provide their initial impressions.
EP. 32: Real World Data for Combination Strategies With Chemotherapy and Immunotherapy in ES-SCLC By Taofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center, Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital, Jacob Sands, MD, Dana-Farber Cancer Institute, Konstantinos Leventakos, MD, PhD Mayo Clinic Faculty discuss real world data for treatment approaches using chemotherapy in combination with immunotherapy in extensive-stage small-cell lung cancer.
EP. 33: Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy By Taofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center, Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital, Jacob Sands, MD, Dana-Farber Cancer Institute, Konstantinos Leventakos, MD, PhD Mayo Clinic A panel of expert oncologists present the case of a 78-year-old woman who is treated with lurbinectedin following disease progress on first-line carboplatin, etoposide, and atezolizumab.
EP. 34: Evolving Treatment Strategies for SCLC in the Second-Line Setting and Beyond By Taofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center, Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital, Jacob Sands, MD, Dana-Farber Cancer Institute, Konstantinos Leventakos, MD, PhD Mayo Clinic Panel experts discuss evolving treatment options for small-cell lung cancer in the second-line setting and beyond.
EP. 35: LAGOON and IMFORTE Trials: Data Updates and Expert Insights By Taofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center, Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital, Jacob Sands, MD, Dana-Farber Cancer Institute, Konstantinos Leventakos, MD, PhD Mayo Clinic A review of the LAGOON and IMFORTE trials with expert insights regarding the potential clinical implications of current and future study findings.
EP. 36: 2L Dosing Considerations and Management Strategies for SCLC By Taofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center, Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital, Jacob Sands, MD, Dana-Farber Cancer Institute, Konstantinos Leventakos, MD, PhD Mayo Clinic Expert oncologists discuss important dosing considerations and treatment management strategies for lurbinectedin and other second-line therapy approaches in small-cell lung cancer.
EP. 37: Novel Treatment Approaches for SCLC and Future Perspectives By Taofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center, Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital, Jacob Sands, MD, Dana-Farber Cancer Institute, Konstantinos Leventakos, MD, PhD Mayo Clinic A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer.
